LivaNova PLC $LIVN Shares Sold by Parkman Healthcare Partners LLC

Key Points

• Parkman Healthcare Partners LLC has reduced its stake in LivaNova PLC by 4.6%, selling 8,063 shares, and now owns 166,871 shares worth approximately $6.56 million.
• Several other institutional investors have significantly increased their holdings in LivaNova, with AQR Capital Management LLC growing its stake by 111.7% during the same period.
• LivaNova reported $1.05 earnings per share for the last quarter, exceeding expectations and showing a 10.6% increase in revenue compared to the previous year.

Parkman Healthcare Partners LLC decreased its holdings in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) by 4.6% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 166,871 shares of the company's stock after selling 8,063 shares during the quarter. Parkman Healthcare Partners LLC owned about 0.31% of LivaNova worth $6,555,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of LIVN. AQR Capital Management LLC grew its holdings in shares of LivaNova by 111.7% during the first quarter. AQR Capital Management LLC now owns 1,571,295 shares of the company's stock worth $60,809,000 after buying an additional 829,115 shares in the last quarter. Nuveen LLC purchased a new position in LivaNova during the first quarter worth about $30,954,000. Hotchkis & Wiley Capital Management LLC raised its stake in LivaNova by 100.7% during the first quarter. Hotchkis & Wiley Capital Management LLC now owns 1,003,000 shares of the company's stock worth $39,398,000 after purchasing an additional 503,350 shares during the period. LSV Asset Management raised its stake in LivaNova by 278.3% during the first quarter. LSV Asset Management now owns 438,498 shares of the company's stock worth $17,224,000 after purchasing an additional 322,598 shares during the period. Finally, Vanguard Group Inc. raised its stake in LivaNova by 13.5% during the first quarter. Vanguard Group Inc. now owns 2,666,880 shares of the company's stock worth $104,755,000 after purchasing an additional 316,993 shares during the period. Hedge funds and other institutional investors own 97.64% of the company's stock.

LivaNova Price Performance

LIVN stock traded up $0.40 during trading on Tuesday, hitting $58.72. The stock had a trading volume of 388,480 shares, compared to its average volume of 621,288. The company's 50 day moving average price is $49.20 and its two-hundred day moving average price is $43.80. LivaNova PLC has a 1-year low of $32.48 and a 1-year high of $58.91. The stock has a market cap of $3.21 billion, a price-to-earnings ratio of -15.10 and a beta of 0.97. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.09 and a current ratio of 1.29.

LivaNova (NASDAQ:LIVN - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported $1.05 earnings per share for the quarter, beating the consensus estimate of $0.84 by $0.21. LivaNova had a negative net margin of 16.13% and a positive return on equity of 14.57%. The firm had revenue of $352.50 million during the quarter, compared to the consensus estimate of $332.20 million. During the same quarter in the previous year, the company posted $0.93 EPS. The firm's revenue for the quarter was up 10.6% on a year-over-year basis. On average, sell-side analysts forecast that LivaNova PLC will post 2.85 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

LIVN has been the topic of a number of analyst reports. Barclays lifted their target price on shares of LivaNova from $55.00 to $58.00 and gave the stock an "equal weight" rating in a research note on Thursday, August 21st. Needham & Company LLC reissued a "buy" rating and set a $64.00 target price on shares of LivaNova in a research report on Wednesday, September 3rd. Wolfe Research raised shares of LivaNova from a "peer perform" rating to an "outperform" rating and set a $60.00 price target for the company in a report on Tuesday, May 20th. Finally, Wall Street Zen upgraded LivaNova from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 9th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $59.71.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.